Enhancement of CpG-based vaccine by 1MT. (A) Wild-type B6 mice with established B16-OVA tumors were treated with adoptive transfer of OT-I cells, with or without 1MT, and with or without vaccine (OVA protein in incomplete Freund adjuvant plus CpG-1826). In parallel experiments, wild-type hosts were compared with RORγt-null bone marrow chimeric hosts (as in Figure 5D) or with MHC class II-deficient (IA^b-KO) hosts. Mean data are indicated, pooled from a total of 8 experiments; bars represent SD. *P < .05 by analysis of variance. (B) B6 mice with B16-OVA tumors received CFSE-labeled OT-I cells plus OVA/CpG/IFA vaccine, with or without 1MT as shown. After 4 days, tumors were disaggregated and stained for CD8 versus granzyme B or CXCR3.